NVIC Articles

Disease-Vaccine-Landing-Page

Disease-Vaccine-Landing-Page

Latest articles

Browse Articles

Placeholder image
Page

Clinical trials on Menactra’s (MCV4 or MenACWY-D) efficacy were not a requirement when FDA licensed its use in 2005. Menactra was the first meningococcal (serogroups A, C, Y, and W-135)...

Placeholder image
Page

Meningococcal vaccine recommendations are scheduled to be reviewed in the next 15 months. Potential changes to the meningococcal recommendations may potentially include the elimination of the age 11–12-year-old meningococcal vaccine...

Placeholder image
Page

On October 20, 2023, the FDA approved PENBRAYA, a meningococcal conjugate vaccine targeting meningococcal serogroups A, B, C, Y, and W-135. This vaccine was approved in individuals between the ages...

Placeholder image
Page

The first meningococcal serogroup B vaccine, TRUMENBA, manufactured by Wyeth (Pfizer) pharmaceuticals, received FDA approval for use in persons aged 10 through 25 years of age on October 29, 2014. ...

Placeholder image
Page

The first meningococcal conjugate vaccine, Menactra, manufactured by Sanofi Pasteur, received FDA approval in January 2005 for use in persons ages 11 through 55 years.  Menactra (MCV4 or MenACWY-D), a...

Placeholder image
Page

Meningococcal vaccine development in the United States began in the 1960s with the organization of a U.S. military meningococcal research group.  Throughout both World Wars, meningococcal disease outbreaks occurred and...

Placeholder image
Page

The CDC recommends that the first dose of meningococcal conjugate vaccine targeting serogroups A, C, Y and W-135 (Menveo or MenQuadfi) be administered at age 11-12 with a second booster...

Placeholder image
Page

Individuals who take eculizumab (Soliris®), a medication often prescribed for paroxysmal nocturnal hemoglobinuria (PNH) or atypical hemolytic uremic syndrome, are also at a higher risk for the disease. Having a low...

Placeholder image
Page

Environmental and biological factors can also increase a person’s risk of developing meningococcal disease. Environmental factors include smoking or living with a smoker, alcohol consumption, and living in crowded environments...

Placeholder image
Page

In 1985, when the CDC’s Advisory Committee on Immunization Practices (ACIP) made its first recommendations on the recently licensed tetravalent meningococcal polysaccharide vaccine targeting serogroups A, C, Y, and W-135...

Topics
Select disease / vaccine